Try our mobile app

General information

Country: UNITED STATES

Sector: Drug Manufacturers — General

AbbVie Inc. researches and develops pharmaceutical products. The Company produces pharmaceutical drugs for specialty therapeutic areas such as immunology, chronic kidney disease, hepatitis C, women"s health, oncology, and neuroscience. AbbVie also offers treatments for diseases including multiple sclerosis, parkinson"s, and alzheimer"s disease.
Website: abbvie.com


  • Bad financial results growth rate -19.4% (average between last period year over year growth for revenue and EBITDA), there is slowdown compared to average historical growth rates (-9.8%)
  • Dividend yield for the last twelve months 2.9%
  • Free cash flow yield 0.2% (LTM)
  • Share price is 73.6% higher than minimum and 5.9% lower than maximum for the last 3 years
  • The company is overvalued by EV / LTM EBITDA multiple compared to target level (48.0x vs
    )
  • Fundamental value created in LTM (estimate)

Key Financials (Download financials)

Ticker: ABBV
Share price, USD:  (0.0%)229.98
year average price 205.66  


year start price 170.67 2025-01-23

min close price 170.16 2025-04-21

max close price 244.38 2025-10-01

current price 229.98 2026-01-22
Common stocks: 1 768 480 508

Dividend Yield:  2.9%
FCF Yield LTM: 0.2%
EV / LTM EBITDA: 48.0x
EV / EBITDA annualized: 56.0x
Last revenue growth (y/y):  +9.1%
Last growth of EBITDA (y/y):  -47.9%
Historical revenue growth:  +1.2%
Historical growth of EBITDA:  -20.9%
Target EV / EBITDA (hist percentile):
Fundamental value created in LTM:
EV / LTM EBITDA mutiple calculation
Market Cap ($m): 406 715
Net Debt ($m): 63 115
EV (Enterprise Value): 469 830
EBITDA LTM ($m): 9 787
EV / LTM EBITDA: 48.0x
Price to Book: -143.3x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / EBITDA

Potential dynamics

News


2026-01-18fool.com

Could Buying This Stock Today Pay Off Big Over the Next 5 Years?

2026-01-16marketbeat.com

AbbVie Call Options Spike 2,599%: Tracking the Big Bet

2026-01-16prnewswire.com

AbbVie Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

2026-01-14seekingalpha.com

AbbVie Inc. (ABBV) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

2026-01-14reuters.com

AbbVie plans to build out its presence in obesity market

2026-01-14zacks.com

Wall Street Bulls Look Optimistic About AbbVie (ABBV): Should You Buy?

2026-01-13zacks.com

ABBV Inks Drug Pricing Deal With Trump, Joins PD-1xVEGF Bandwagon

2026-01-13zacks.com

Will AbbVie's Oncology Segment Support Top-line Growth in Q4 Earnings?

2026-01-13barrons.com

AbbVie Strikes a $100 Billion Deal With Trump. How the Drugmaker Will Dodge Tariffs.

2026-01-12prnewswire.com

AbbVie and Trump Administration Reach Agreement to Improve Access and Affordability for Americans
More information for subscribed users:
detailed calculation of
Potential and Created Value,
website traffic data